



The National Colorectal Cancer Screening Program in Croatia: how it started and where we are?



Assistant professor Nataša Antoljak, MD, PhD



Comitee for Organisation, Monitoring and Quality Control of National Colorectal Cancer Screening Program

Croatian National Institute of Public Health, Epidemiology service

and

**University of Zagreb, School of Medicine, School of Public Health "Dr A. Štampar",
Department for medical statistic, epidemiology and medical informatics**





Incidence and mortality rate

INCIDENCE:

1990.g.- 1648 (34,5/100.000)

2010.g.- 3068 (69,4/100.000)

↑ 86%, ↑ rate 100%! **CAUSES?**

1827 Males (85,6/100.000), 1241 Females (54,3/100.000)

MORTALITY:


1990.g.- 1049 (21,9/100.000)

2011.g.- 2009 (45,5/100.000)

↑ 92%, ↑ rate 108%


1164 Males, 845 Females

Incidence and mortality rate



Data: cancer registry and mortality base (CNIPH, Federal bureau of statistics)

CRC localization in time of diagnose




■ localized ■ distant metastazes ■ regional lymph node met. ■ no data

Data: cancer registry Croatian national institute of public health


Standardized death rate-country comparison

SDR, Malignant neoplasm of colon, rectum and anus, per 100000



Data: WHO Europa, Health for all

Current organization





Current results

- included 1.414.466 (99%) persons who were sent test-package
- returned 287.808 envelopes (with or without specimens)-20.3% (according to EU guidelines in 1. cycle, expected values for national program: 17.2-70.8%)
- analysed 246.750 persons (3 test cards for each)
- FOBT positive persons: 15.494 (6,3%)→better compliance in already symptomatic people, hipersensitive test (EU quidelines expected values: 1.5-8.5%)


(data obtained by PHI and CNIPH coordinators)



Colonoscopy

- colonoscopy done in 10439 people (80%)
- persons diagnosed with **carcinoma: 560-2.3/1000** of tested (**EU guidelines: 1.2-2.3/1000**)
- persons diagnosed with polyp(s): **4112-39%** of colonoscoped persons (**EU guidelines: to 36,3%**)
- 800 persons-negative (false positive-**9%**)
- persons diagnosed with haemerhoids: 2972
- persons diagnosed with diverticula or other diseases: 1728

Geographic, resources and population diversity-organizational challenge



Response rate before organized screening-6%!



Comparison-Slovenia, SVIT

- centralised system
- in pilot-response was in 2009.-36%
- 2010-57%
- 2011.-66%-**effective promotive and educational activities**
- now-70% crc detected in program!

Financial aspect

- costs for crc treatment in Slovenia-45.450.000 Eur
- year costs of program-5.000.000 Eur
- after 2 years they save 3.998.000 Eur
- after 5 years total save 20 mil. Eur


Place for empowerment

- in 4 years 560 persons were diagnosed crc
- three times program was stoped (public procurement law, other law changes during EU accession procedure)
- 2011.-just 21 persons were diagnosed→we missed to detect CRC in 130 persons, and in cca 1100 persons detect and remove polyp
- each year incidence is 3000 people
- if we arise compliance to accepted values (45%) till now we could detect CRC in 1350 persons/year, and remove polyps in 7500!





What is connection between meteorology and CRC screening?





FOBT

- probability of the iFOBT being positive-17% lower in summer than in winter
- increase in temperature of 1°C - 0.7% reduction in probability of a FOBT being positive
- the probability of detecting a cancer or an advanced adenoma in the summer was about 13% lower than in the winter
- in Croatia more than 2/3 of year, temperature above 20°C, in post-cases about 24-25°C if placed on sunshine
- iFOBT testing must be centralized, educated personel, informatically connected to CRC-screen aplication



■ Reorganization

- first phase added-invitation letter
- educational and promotional activities, continue previous activity of Croomsic-medical student organization-**"stolica glavu čuva"**, **"mRak kampanja"**
- new unique visual identity together with new program for cervical cancer, and well organized breast cancer program
- planned renewal of informatic application and connection with primary care CEZIH
- planned more active inclusion of primary care physicians, nurses, and field nurses (patronage)

NO CHANGES:

- 3 card/each 4 window gFOBT, stabile to transport in pvc bags
- mailing FOBT to home addresses
- organization-public health institutes, hospital colonoscopy units with pathology units

Primary care physicians, patronage nurses-
informing eligible population before
invitations,

eligible population M and F 50-74 yrs.

Letter-invitation for testing, brochure,
addressed envelop to local public health institute

no response or dislike testing,
second invitation, PCP, patronage

returned with information: dead,
temporary absent, unknown
(noncompliance)

person already have crc or
done testing or colonoscopy
in ast 2 years

returned answer, signed informed
conset that like testing

send envelop with 3 card tests, prescription, questionnaire, pvc
sealed package-patient returne specimens to institute

non-compliancecauses

correctly placed specimens
on all 3 cards and fulfilled
questionaire

NEGATIVE- invitation after
2-3 years in next cycle

returned empty or fulfilled questionnaire or
incorrectly placed specimens or cards
without specimen-about 3% (in most cases
tel. number and name of PCP, about 1/3
never send another specimen)

POZITIVE-invitation to
colonoscopy+purisan+instructions

INFORMATION to primary
care physician

within 6 weeks

consultation and additional advices at primary care
physician

POZITIVE- Cancer-phd and final
diagnose at colonoscopy unit
NOT TO BE INVITED IN NEXT
CYCLE! (STILL NOT APPLICABLE)

POZITIVE, OTHER DISEASES OF
COLON OR RECTUM-instructions for
management at colonoscopy unit

POZITIVE, POLYP-POLIPECTOMY at
same, eventually next colonoscopy
(regular procedure), waiting for phd
and final diagnose at colonoscopy unit
NOT TO BE INVITED IN NEXT CYCLE!
(STILL NOT APPLICABLE)

NEGATIVE- INVITATION IN
NEXT CYCLE AFTER 2 YEARS

INFORMATION to primary
care physician

additional exams and staging of
disease
THERAPY, TREATMENT

OUT OF
PROGRAM

CANDB - Windows Internet Explorer

http://192.168.14.7/inputs/colology/1189526/

File Edit View Favorites Tools Help

Favorites Suggested Sites Free Hotmail Web Slice Gallery

CANDB

Suzenje lumena:
 Bolnost:
 Nedovoljno ciscenje:
 Na zahtjev bolesnika:
 Ostalo:

Ostalo

Ulcerozni kolitis	Morbus Crohn	Ostali kolitisi
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Komplikacije

		Ima komplikacije	Nema komplikacije
Vrijeme nastanka			
Tijekom kolonoskopije	nakon kolonoskopije	do 7 dana	do 30 dana
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Vrsta komplikacije			
Krvarenje	Perforacija	Kardiorespiratorni poremećaj	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Ishod liječenja komplikacije			
Konzervativno/endoskopski	Kirurški zahvat	Smrt	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Inspekcija anokutane regije: nalaz uredan.
 DRF: nalaz uredan, uvećana prostata, na prstu rukavice oskudan krvav trag.
 Kolonoskopski nalaz: učinjena totalna kolonoskopija. U analnom kanalu lako podraženi unutarnji hemoroidi. U sigmi veći broj ovećih i dubokih divertikula. U ostalom dijelu nema promjena. Valvula Bauhini voluminoznija.
 terminalna ileoskopija: bez poteškoća se uđe u terminalni ileum. Pregleda se oca 30 cm tankog crijeva koje je uredne suznice.

Misljenje (DG) endoskopicara o uzroku pozitivnog nalaza:

Dg: Moduli hemorrhoidales interni
 Dr. Bonacin

Završno misljenje gastroenterologa-endoskopicara:

Unesi

Done

Internet 100%

International ColoRectal Cancer Screening Network

An international consortium of organised initiatives delivering colorectal cancer (CRC) screening to their populations



© Shutterstock © Logo P. Villain

[Home](#) | [Activities](#) | [Members](#) | [Events](#) | [Publications](#) | [Documents](#) | [Contact](#) | [Res](#)

The ICRC SN members (in alphabetical order of country's name):

- Australia: Ms Andriana Koukari, Professor Graeme Young
- Canada: Dr Heather Bryant, Professor Linda Rabeneck, Ms Jean Sander, Dr Laura Sware, Dr Huiming Yang
- Chile: Dr Francisco López-Kostner
- Czech Republic: Dr Štěpán Suchánek, Professor Miroslav Zavoral
- Croatia: Dr Nataša Antoljak
- Finland: Dr Nea Malila
- France: Dr Rosemary Ancelle-Park, Dr Emmanuelle Salines, Dr Jérôme Viguier, Dr Lawrence Von Karsa
- Germany: Dr Lutz Altenhofen, Dr Gerhard Brenner
- Hong Kong: Professor Joseph Jao-Yiu Sung
- Hungary: Dr László Herszényi, Professor Zsolt Tulassay
- Israel: Dr Gad Rennert
- Italy: Dr Nereo Segnan, Dr Carlo Senore, Dr Marco Zappa



European Guidelines for Quality Assurance in Colorectal Cancer Screening



European Commission

WJG World Journal of Gastroenterology
 Online Submission: <http://www.wjgnet.com/wjg/> World | Gastroenterol 2012 August 26; 18(32): 4300-4307
 ISSN 1007-9327 (print) ISSN 2219-2649 (online)
 doi:10.5734/wjg.v18.i32.4300 © 2012 Baisheng. All rights reserved.

Results of National Colorectal Cancer Screening Program in Croatia (2007-2011)

Miroslava Katičić, Nataša Antoljak, Milan Kužundžić, Valerija Stamenić, Durijs Skoko Poljak, Danica Kramarić, Davor Štamac, Marija Štrnad Pešikan, Mirko Šamija, Zdravko Ebling

Miroslava Katičić, Department of Gastroenterology, Mekuša University Hospital, 10000 Zagreb, Croatia
Nataša Antoljak, Croatia Main Disease Epidemiology Service, Croatian National Institute of Public Health and Zagreb University School of Medicine, Dr. Andrija Stampar School of Public Health, 10000 Zagreb, Croatia
Milan Kužundžić, Department of Gastroenterology, Dubrava University Hospital, 10000 Zagreb, Croatia
Valerija Stamenić, Durijs Skoko Poljak, Danica Kramarić, Ministry of Health and Social Welfare, 10000 Zagreb, Croatia
Davor Štamac, Department of Gastroenterology, Rijeka University Hospital Center, 51000 Rijeka, Croatia
Marija Štrnad Pešikan, Zagreb University School of Medicine, Dr. Andrija Stampar School of Public Health, 10000 Zagreb, Croatia
Mirko Šamija, Zagreb University School of Medicine, 10000 Zagreb, Croatia
Zdravko Ebling, Opatjak Health Center, 31000 Opatjak, Croatia
Author contributions: Katičić M and Antoljak N designed the study, ensured the acquisition, analysis, and interpretation of data and wrote the first draft; Stamenić V, Štrnad Pešikan M, Šamija M and Ebling Z designed a plan of Colorectal National Screening Program and critically revised this paper; Kužundžić M and Štamac D were involved in supervisory and supportive activities during program implementation; Skoko Poljak D and Kramarić D ensured funding, administration, technology and material support.
Correspondence to: Dr. Katičić Miroslava, Professor, Department of Gastroenterology, Mekuša University Hospital, Zajčeva 19, 10000 Zagreb, Croatia. mikati@mekeusa.hr
 Telephone: +385-1-2308461 Fax: +385-1-3130250
 Received: June 16, 2012
 Accepted: August 18, 2012
 Published online: August 28, 2012

and leading cause of cancer mortality in men ($n = 2065$, 49.7/100 000), as well as women ($n = 805$, 34.8/100 000) in Croatia in 2009. The Croatian National CRC Screening Program was established by the Ministry of Health and Social Welfare, and its implementation started in September, 2007. The coordinators were recruited in each county institute of public health with an obligation to provide fecal occult blood testing (FOBT) to the participants, followed by colonoscopy in all positive cases. The FOBT was performed by hypersensitive guaiac-based Hemogest card test (Diagnost, Zagreb). The test and short questionnaire were delivered to the home addresses of all citizens aged 50-74 years consecutively during a 3-year period. Each participant was required to complete the questionnaire and send it together with the stool specimen on three test cards back to the institute for further analysis. About 4% FOBT positive cases are expected in normal risk populations. A descriptive analysis was performed.

RESULTS: A total of 1 056 694 individuals (born between 1933-1945 and 1962-1967) were invited to screening by the end of September 2011. In total, 230 239 (21.9%) persons returned the envelope with a completed questionnaire, and 181 102 of them returned it with a correctly placed stool specimen on FOBT cards. Until now, 12 477 (6.9%), FOBT-positive patients have been found, which is at the upper limit of the expected values in European Guidelines for Quality Assurance in CRC Screening and Diagnosis (European Union (EU) Guidelines). Colonoscopy was performed in 8541 cases (uptake 69%). Screening has identified CRC in 472 patients (5.3% of colonoscoped, 4.8% of FOBT-positive, and 0.26% of all screened individuals). This is also in the expected range according to EU Guidelines. Polyps were found and removed in 3329 (39% of colonoscoped) patients. The largest number of polyps were found in the left half of the colon: 64% (19%, 37% and 0% in the rectum, sigmoid, and descending, respectively). The other 36% were

Abstract

AIM: To study the epidemiologic indicators of uptake and characteristic colonoscopic findings in the Croatian National Colorectal Cancer Screening Program.

METHODS: Colorectal cancer (CRC) was the sec-



Skinuti zaštitnu traku s posudice podložka

Sanitarni podložak

Pomoćno sredstvo za uzimanje uzoraka stolice
Sanitarni podložak služi za sigurno i higijenski
sakupljanje uzoraka stolice, potrebnih za dovođenje
pouzdanih rezultata pretraga



Skinuti zaštitne trake sa sanitarnog podložka i
zaljepiti ga na dasku WC školjke. Pri tome paziti da
podložak ne dođe u dodir s vodom, sredstvom za
čišćenje ili osvježavanje WC školjke.
Uzorak stolice uzeti u skladu s uputama.

Skinuti zaštitnu traku s posudice podložka



Nakon uzimanja uzorka, istovremeno odlijepiti oba
kraja podložka s dasko i sipati u školjku. Kako bi
se izbjekao odvod, prije ispiranja WC školjke
pričekati da papir natekša.

Preporuča se korištenje BioGnostovog sanitarnog
podložka bez obzira na vrstu WC školjke, u
zdravstvenim ustanovama i za kućna testiranja.

Prodavni d.o.o. - Medicinska 60, 10040 Zagreb
tel: +385 1 2469 9977, fax: +385 1 2464 039
biognost@biognost.hr, www.biognost.hr

HEMOGNOST® TEST KOMPLET

UPUTA ZA PACIJENTE
POSTUPAK SAKUPLJANJA UZORAKA STOLICE

Slikovni prikaz na drugoj strani →

NAMJENA I SASTAV TESTA

HemoGnost test karton je brzi test za otkrivanje skrivenog (nevidljivog, okultnog) krvarenja u stolici.
Komplet se sastoji od tri HemoGnost test kartona, 12 kartonskih štapića, upute za korisnike i povratne kuverte s vrećicom za zaštitu uzorka. Može sadržavati i 3 sanitarna podloška.

UVOD

HemoGnost test karton je jednostavan test kojim je moguće ustanoviti postoji li u stolici (izmetu) golim okom nevidljivo krvarenje, jer takvo krvarenje ima dijagnostički značaj u ranom otkrivanju zloćudnih bolesti debelog crijeva.

UPUTE ZA KORISNIKA PRIJE SAKUPLJANJA UZORKA STOLICE

Kako bi testiranje bilo pouzdano, potrebno je dobro proučiti ovu uputu jer neke bolesti i stanja mogu djelovati na rezultate testiranja. Potrebno je pridržavati se dolje navedenih preporuka:

- Test treba odgoditi krvarete li iz hemoroida ili mokracačovoda, ili imate proljev ili menstruaciju.
- Sakupite uzorke iz tri stolice tijekom tri različita dana i to po četiri uzorka s različitim mjestima iz svake stolice.
- Ne uzimajte vitamin C (askorbinska kiselina) u količini većoj od 250 mg dnevno tri dana prije testiranja. To se odnosi i na dodatke hrani koji sadrže askorbinsku kiselinu, limune i naranče, voće i sokove. Npr. prosječna naranča sadrži 70-75 mg vitamina C.

Prije početka testiranja obavezno pročitati ovu uputu za izvođenje testa i upoznat se s izgledom HemoGnost test kartona.

Test karton sastoji se od prednje strane na kojoj se nalazi veliki poklopac i naziv testa HEMOGNOST, i stražnje strane na kojoj se nalaze dva manja poklopca s naznakom da je poklopac dozvoljeno otvoriti samo u laboratoriju. **Pacijent prilikom testiranja otvara i zatvara samo veliki poklopac na prednjoj strani testa, dok se stražnju stranu testa ne smije dirati.**

VAŽNO!

- Spriječiti doticaj stolice s vodom u zahodu stavljanjem presavinutog novinskog papira na površinu vode. Nakon uzimanja uzorka, isprati zahod. Ako je priložen, na dasku postaviti sanitarna podloška.
- Zaštititi HemoGnost test karton od prekomjerne hladnoće, vlage, topline i izravnog sunčevog svjetla.
- HemoGnost test karton čuvati na sobnoj temperaturi izvan dohvata djece.
- HemoGnost test karton s nanijetim uzorcima stolice poslati u zdravstvenu ustanovu unutar 7 dana od sakupljanja prvog uzorka.

POSTUPAK TESTIRANJA (tijekom tri dana)

1. Na prednju stranu HemoGnost test kartona napisati: IME, PREZIME, ADRESU I DATUM.



2. Otvoriti prednji veliki poklopac HemoGnost test kartona. Otvara se na donjem dijelu gdje se nalazi crvena strelica i natpis "OTVORITI OVDJE".



3. Priloženim kartonskim štapićem nanijeti uzorak stolice veličine zrna pšenice i namazati ga u tanom sloju unutar kruga označenog slovom A.



4. Ponoviti isti postupak na površinama polja B, C i D uzimajući novim kartonskim štapićima uzorke s raznih dijelova stolice.



5. Zatvoriti poklopac HemoGnost testa tako da se zakači na mjestu označenom crvenom strelicom i natpisom "ZATVORITI OVDJE". Taj natpis postaje vidljiv tek nakon što se otvori prednji veliki poklopac. (Vidi slike!)



6. Spremiti karton u priloženu vrećicu za slanje u zdravstvenu ustanovu.




Ponoviti postupak na identičan način i drugi i treći dan, uz upotrebu **NOVOG HemoGnost test kartona i NOVIH, ČISTIH kartonskih štapića.**

Sva tri HemoGnost test kartona zatvoriti u vrećicu, staviti u priloženu kuvertu i ubaciti u poštanski sandučić.



Slikovni prikaz na drugoj strani →







COMING TOGETHER IS A BEGINNING ,
KEEPING TOGETHER IS PROGRESS,
WORKING TOGETHER IS SUCCESS